Glucose Disorders Induced by Tacrolimus on Pre Transplantation Endstage Renal Disease Patients (GLITTER)

Diabetes after kidney transplantation is a frequent complication, the incidence of which varies from 7 to 45% depending on the studies and on the diagnostic criteria used. Post-transplant diabetes is an early complication, most often occurring in the first month after transplantation.

In addition to the additional health costs generated by the appearance of post-transplant diabetes, the risk of graft loss is increased by 60% and the overall mortality risk by 90%. Similarly, the development of glucose intolerance after transplantation is associated with higher mortality.

Tacrolimus treatment is therefore currently one of the most important risk factors for diabetes at the time of transplantation.

Indeed, several in vitro and in vivo animal studies have shown that tacrolimus alters pancreatic endocrine function.

In the final stage, this cellular toxicity leads to diabetes, most often diagnosed on the rise in capillary or venous blood sugar levels after transplantation. This diabetes often requires hypoglycemic treatment with insulin or oral anti-diabetic drugs. for a variable period. The pro-diabetogenic effect of tacrolimus is sometimes irreversible, justifying preventive treatment.

No clinical studies have looked at "sub-clinical" changes in insulin secretion or insulin resistance under tacrolimus prior to the onset of diabetes. The static indices HOMA-β% and HOMA-IR (Homeostasis Model Accessment of insulin resistance) make it possible to estimate insulin secretion and insulin resistance in fasting patients respectively, while the oral glucose disposition index (IDO) makes it possible to study insulin secretion and action dynamically (after a 75 g glucose load), and are calculated as follows:

HOMA IR= Fasting blood glucose (mmol/L) x Fasting insulin (mU/L)/ 22.5 HOMAβ% = 20 x fasting insulinemia (mU/L) / fasting plasma glucose (mmol/L) - 3.5 IDO = (delta insulinemia T30-T0/ delta blood glucose T30-T0)/insulinemia T0

These indices have already been studied in dialysis patients (diabetic and non-diabetic) and may allow a more detailed study of pancreatic response and insulin resistance under tacrolimus in patients prior to renal transplantation. Determining the "pancreatic response" to tacrolimus in patients prior to transplantation would prevent diabetes by adapting immunosuppressive treatment and post-transplant screening modalities in the event of pre-transplant subclinical abnormalities identified in our study. The development of tacrolimus-induced diabetes in pre-transplantation in our study will be a contraindication to tacrolimus at the time of transplantation and ciclosporin therapy will be preferred.

Study Overview

• Status: Recruiting
• Conditions: Kidney Failure, Chronic
• Intervention / Treatment: Drug: Tacrolimus

• Study Type: Interventional
• Enrollment (Anticipated): 30
• Phase: Phase 4

Contacts and Locations

• Study Contact: Name: Chloé MOREAU; Phone Number: 0251446572; Email: chloe.moreau@chd-vendee.fr

Study Locations

• France
  • La Roche-sur-Yon, France
    • Recruiting
    • Centre Hospitalier Départemental Vendée
    • Principal Investigator: Awena LE FUR
  • Nantes, France
    • Recruiting
    • Centre Hospitalier Universitaire Nantes
    • Principal Investigator: Jacques DANTAL

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Age ≥ 18 years
• Patient eligible for kidney transplantation at the Nantes University Hospital
• Hemodialysis patient in one of the participating centres
• Patient who is able to understand the proposed protocol and has given free and informed consent
• Patient with affiliation to the French social security system.

Exclusion Criteria:

• Personal history of diabetes treated or untreated
• Temporary contraindication for carcinological reasons
• Immunosuppressive treatment in the 6 months prior to inclusion
• Macrolide Allergies
• Hypersensitivity to the excipients used in the composition of tacrolimus
• Intolerance to the HGPO test
• Progressive infectious outbreak
• Hepatic insufficiency
• Intercurrent infectious pathology
• Patient under guardianship, curatorship, legal protection measure, or deprived of liberty
• Pregnant women, breastfeeding, or non-menopausal woman who refuses contraception

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Diagnostic
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Tacrolimus treatment	Drug: Tacrolimus; Tacrolimus will be initiated at 0.1 mg/kg/day in two separate 12-hour oral doses (capsules) for 14 days.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Proportion of haemodialysis patients modifying their glycemic profile receiving Tacrolimus	During 14 days

Collaborators and Investigators

• Sponsor: Centre Hospitalier Departemental Vendee
• Investigators: Principal Investigator: Awena LE FUR, CHD Vendee

Study record dates

Study Major Dates

• Study Start (Actual): March 8, 2019
• Primary Completion (Anticipated): April 1, 2025
• Study Completion (Anticipated): July 1, 2025

Study Registration Dates

• First Submitted: August 17, 2018
• First Submitted That Met QC Criteria: August 17, 2018
• First Posted (Actual): August 21, 2018

Study Record Updates

• Last Update Posted (Actual): March 22, 2023
• Last Update Submitted That Met QC Criteria: March 21, 2023
• Last Verified: March 1, 2023

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Kidney Diseases; Urologic Diseases; Renal Insufficiency, Chronic; Kidney Failure, Chronic; Renal Insufficiency; Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Enzyme Inhibitors; Immunosuppressive Agents; Immunologic Factors; Calcineurin Inhibitors; Tacrolimus
• Other Study ID Numbers: CHD045-17

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No